2-(4-methoxyphenyl)-1H-imidazole-4-carboxylic acid | 279250-99-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-methoxyphenyl)-1H-imidazole-4-carboxylic acid
• 英文别名: 2-(4-methoxyphenyl)-4-carboxy-1H-imidazole；4-Carboxy-2-(4-methoxyphenyl)-1H-imidazole；2-(4-methoxyphenyl)-1H-imidazole-5-carboxylic acid
• CAS: 279250-99-6
• 化学式: C₁₁H₁₀N₂O₃
• 分子量: 218.212
• InChiKey: YAUSOSAHTJLYAX-UHFFFAOYSA-N

物化性质

• 熔点：
  233-235 °C
• 沸点：
  515.6±30.0 °C(Predicted)
• 密度：
  1.340±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  75.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-methoxyphenyl)-1H-imidazole-4-carboxylic acid 在 lithium aluminium tetrahydride 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 二异丙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 20.0h， 生成 2-(4-methoxyphenyl)-1H-4-imidazolcarbaldehyde
  参考文献：
  名称：

  Synthesis, Structure, and Neuroprotective Properties of Novel Imidazolyl Nitrones

  摘要：

  A new series of imidazolyl nitrones spin traps has been synthesized and evaluated pharmacologically. The salient structural feature of these molecules is the presence of an imidazole moiety substituted by aromatic or heteroaromatic cycles. This connectivity imparts to the nitrone superior neuroprotective properties in vivo and in parallel reduced side effects and toxicity. Thus compound 6a (a 2-phenylimidazolyl nitrone) administered intraperitoneally protects (80%) mice from lethality induced by an intracerebroventricular administration of tert-butyl hydroperoxide (t-BHP) an oxidant capable of inducing neurodegenerative processes. Administration of the archetypal nitrone phenyl-tert-butyl nitrone (PBN) at an equimolar dose also affords some protection (60%) in this test. However, this activity is accompanied by hypothermia, whereas no such effect is apparent for 6a. Moreover, previously prepared nonsubstituted or alkyl-substituted imidazolyl nitrones were shown to be extremely toxic to rats in contrast to the compounds prepared in this study. The observed activities in vivo correlate well with the calculated partition coefficients (ClogP) and HOMO energy level.

  DOI：

  10.1021/jm991154w
• 作为产物：
  描述：

  4-甲氧基苯甲醛 在 乙醇 、 水 、 sodium acetate 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 2.5h， 生成 2-(4-methoxyphenyl)-1H-imidazole-4-carboxylic acid
  参考文献：
  名称：

  Discovery of novel 2-aryl-4-bis-amide imidazoles (ABAI) as anti-inflammatory agents for the treatment of inflammatory bowel diseases (IBD)

  摘要：

  DOI：

  10.1016/j.bioorg.2022.105619

文献信息

• [EN] HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS À PETITES MOLÉCULES MIMÉTIQUES DES FACTEURS DE CROISSANCE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS
  申请人：LIGAND PHARM INC

  公开号：WO2011046954A1

  公开（公告）日：2011-04-21

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  目前的实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。目前的实施例还涉及利用这些化合物来治疗各种疾病、疾病和疾患，如造血状况和疾病。
• [EN] BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZÈNESULFONAMIDE EN TANT QUE MODULATEURS TRAP1 ET UTILISATIONS ASSOCIÉES
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188880A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了Formula (I)的化合物及其药用盐、溶剂化合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记化合物和其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能在PTEN诱导激酶1（"PINK1"）功能丧失的情况下恢复活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，并/或减少活性氧自由基的产生。所提供的化合物还可能对α-突触核蛋白等聚集或错误折叠的蛋白进行重新折叠或溶解。本公开还提供了包含所提供化合物的药物组合物；包含所提供化合物或药物组合物的试剂盒；以及使用所提供化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• 一种具有杀菌活性的咪唑类药物分子及其制 备方法
  申请人：河南科技大学第一附属医院

  公开号：CN110256357B

  公开（公告）日：2020-05-01

  本发明公开了一种具有杀菌活性的咪唑类药物分子及其制备方法，属于抗菌药物的合成技术领域。本发明的技术方案要点为：该咪唑类药物分子具有结构本发明通过以对甲氧基苯甲酸为起始原料，先与氨基乙酸乙酯在缩合试剂作用下反应得到N‑乙酸乙酯基‑对甲氧基苯甲酰胺，再与劳森试剂反应得到N‑乙酸乙酯基‑对甲氧基硫代苯甲酰胺，与碘甲烷反应得到2‑(((4‑甲氧基苯)(甲硫基)(亚甲基)(氨基)醋酸乙酯，然后2‑(((4‑甲氧基苯)(甲硫基)(亚甲基)(氨基)醋酸乙酯与甲酰胺缩合后环合，再水解得到2‑(4‑甲氧基苯基)‑1H‑咪唑‑4‑羧酸，最后与间甲基苯乙醇发生酯化反应得到目标化合物。通过微量二倍稀释法进行抗菌活性测试，发现目标化合物具有一定的抗菌作用。
• Nitrone compounds
  申请人：Adir Et Compagnie

  公开号：US06034250A1

  公开（公告）日：2000-03-07

  A compound selected from those of formula (1): ##STR1## wherein W represents aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each being optionally substituted, R.sub.1 represents alkyl, alkenyl, alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl, each being optionally substituted. R.sub.2 is as defined in the description, its isomers, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful as anti-oxidation agents.

  从以下化学式（1）中选择的一种化合物：##STR1## 其中W代表芳基，芳基烷基，杂环芳基或杂环芳基烷基，每种都可以被取代，R.sub.1代表烷基，烯烃基，炔烃基，芳基，环烷基，芳基烷基或环烷基烷基，每种都可以被取代。R.sub.2如描述中所定义，其异构体，以及与药学上可接受的酸或碱形成的加合盐，以及含有这种化合物的药品，可用作抗氧化剂。
• HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES
  申请人：Zhi Lin

  公开号：US20120295904A1

  公开（公告）日：2012-11-22

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  本实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。本实施例还涉及使用这些化合物来治疗各种状况、疾病和疾病，例如造血系统状况和疾病。